News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aqua Pharmaceuticals Announces FDA Approval Of ACTICLATE™ (Doxycycline Hyclate USP) Tablets, 150 Mg And 75 Mg



7/28/2014 8:52:02 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WEST CHESTER, Pa.--(BUSINESS WIRE)--West Chester-based Aqua Pharmaceuticals, an Almirall company, today announces the U.S. Food and Drug Administration (FDA) approval of the NDA for ACTICLATE™ (doxycycline hyclate USP) Tablets, 150 mg and 75 mg, thereby continuing Aqua’s leadership in medical dermatology and oral antibiotics for acne. ACTICLATE™ is a tetracycline-class antibacterial indicated for the treatment of a number of infections, including adjunctive therapy in severe acne.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES